Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Eye fluid test may personalize uveitis treatment

NCT ID NCT07262437

Knowledge-focused Sponsor: University of Milan Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether analyzing fluid from the eye can predict which immunosuppressive drug will work best for people with non-infectious uveitis, an eye inflammation condition. About 220 participants who haven't responded well to steroids will provide eye fluid and blood samples. Researchers will measure immune signals in the fluid and compare them to how patients respond to standard drugs like methotrexate or adalimumab. The goal is to make treatment more personalized and effective.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors choose the right immunosuppressive drug for each uveitis patient, improving treatment outcomes.
What could go wrong
This is an observational study, not a treatment trial. It may not lead to immediate changes in care, and results might not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 220 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2025

Expected to finish

Jul 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of non-infectious uveitis in at least one eye with incomplete or not sustained response to topic or systemic steroids at the baseline visit * Evidence of anterior chamber inflammation to optimize lab sensibility * As per clinical practice eligibility to receive one of the following immunosuppressive treatment: mycophenolate mofetil (MMF), methotrexate (MTX), azatioprine (AZA), adalimumab (ADA) * Ability to provide informed consent Exclusion Criteria: * Concomitant immunosuppressive treatment * Presence of other systemic pathologies that do not allow immunosuppressive therapies * Ocular media opacities that could interfere with a good quality of fundus exam and/or imaging of the eye * Any ocular or systemic condition that could interfere with cytokine profile expressions * Pregnancy or breastfeeding

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Inflammation eye are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

anterior uveitis endophthalmitis Inflammation posterior uveitis uveitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Inflammation eye Uveitis Uveitis posterior non-infectious Uveitis, anterior

Contacts and locations

Locations

  • ASST Fatebenefratelli Sacco P.O.L.Sacco

    Milan, 20157, Italy

  • AUSL Reggio Emilia

    Reggio Emilia, 42122, Italy

  • IRCCS San Raffaele Università Vita e Salute

    Milan, 20132, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.